Skip to main content
SpringerLink
Log in

Schwerpunkt "Primäre Lebertumoren"

Fortgeschrittenes HCC: Was sind die wirksamsten Systemtherapien?

  • Schwerpunkt
  • Published:
InFo Hämatologie + Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

Literatur

  1. Llovet JM et al. Sorafenib in Advanced Hepatocellular Carcinoma. N Engl J Med. 2008;359(4):378-90

  2. Kudo M et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163-73

  3. Finn RS et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894-1905

  4. Abou-Alfa GK et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018;379(1):54-63

  5. Bruix J et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56-66

  6. Zhu AX et al. REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib. J Clin Oncol. 2018;36(15_suppl):4003

  7. Zhu AX et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940-52

  8. El-Khoueiry AB et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492-502

  9. Finn RS et al. KEYNOTE-240: Randomized phase III study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma. J Clin Oncol. 2017;35(4_suppl):TPS503

  10. Yau T et al. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2019;30(suppl 5):v874-v875

  11. Yau T et al. Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. J Clin Oncol. 2019;37(15_suppl):4012

  12. Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019;380(15):1450-62

  13. Llovet JM et al. Hepatocellular carcinoma. Nat Rev Dis Prim. 2021;7(1):6

  14. Llovet JM et al. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329-38

  15. Galle PR et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182-236

  16. Marrero JA et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. J Hepatol. 2016;65(6):1140-7

  17. Zhu AX et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma analysis of REACH trial results by child-pugh score. JAMA Oncol. 2017;3(2):235-43

  18. Finkelmeier F et al. Nivolumab for the treatment of hepatocellular carcinoma. Expert Rev Anticancer Ther. 2018;18(12):1169-75

  19. Kudo M et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2020;69(8):1492-1501

  20. Lencioni R et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. J Hepatol. 2016;64(5):1090-8

  21. Casadei-Gardini A et al. Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis. Liver Int. 2021;41(6):1389-97

  22. Finn RS et al. IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol. 2021;39(3_suppl):267

  23. Galle PR et al. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(7):991-1001

  24. Pinter M et al. Immunotherapy for advanced hepatocellular carcinoma: A focus on special subgroups. Gut. 2021 ;70(1):204-14

  25. https://www.leitlinienprogramm-onkologie.de/leitlinien/hcc-und-biliaere-karzinome; abgerufen am 5. August 2021

  26. Vogel A et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(suppl 4):iv238-iv255

  27. Finkelmeier F et al. Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort. Liver Cancer. 2021;10(4):360-9

  28. Tovoli F et al. Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma. Liver Cancer. 2021;10(4):370-9

  29. Galle PR et al. Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol. 2020;38(suppl 4):476

  30. Pinter M et al. The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review. JAMA Oncol. 2021;7(1):113-23

  31. Haanen JBAG et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv119-iv142

  32. https://www.leitlinienprogramm-onkologie.de/leitlinien/supportive-therapie; abgerufen am 5. August 2021

  33. Pfister D et al. NASH Limits Anti-Tumour Surveillance in Immunotherapy-Treated HCC. Nature. 2021;592(7854):450-6

  34. Bangaru S et al. Review article: new therapeutic interventions for advanced hepatocellular carcinoma. Aliment Pharmacol Ther. 2020;51(1):78-89

  35. Kirstein MM et al. Sequential systemic treatment in patients with hepatocellular carcinoma. Aliment Pharmacol Ther. 2020;52(1):205-12

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik 1 und Universitäres Tumorzentrum, Universitätsklinikum Frankfurt, Goethe-Universität, Frankfurt, Deutschland

    Vera Himmelsbach,  Fabian Finkelmeier &  Oliver Waidmann

Authors
  1. Vera Himmelsbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fabian Finkelmeier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Oliver Waidmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Oliver Waidmann.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Himmelsbach, V., Finkelmeier, F. & Waidmann, O. Fortgeschrittenes HCC: Was sind die wirksamsten Systemtherapien?. InFo Hämatol Onkol 24, 15–20 (2021). https://doi.org/10.1007/s15004-021-8778-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-021-8778-4

Search

Navigation